InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

November 21, 2022

Read More »

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

November 18, 2022

Read More »

InMed Provides Update on Management Changes

November 17, 2022

Read More »

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

November 16, 2022

Read More »

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

November 11, 2022

Read More »

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

November 10, 2022

Read More »

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

October 26, 2022

Read More »

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

September 23, 2022

Read More »

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

September 13, 2022

Read More »

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

September 9, 2022

Read More »

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

September 8, 2022

Read More »

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

August 23, 2022

Read More »

InMed Announces Changes to its Board of Directors

August 9, 2022

Read More »

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

July 25, 2022

Read More »

InMed Announces Appointment of Chief Operating Officer

July 18, 2022

Read More »

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

July 12, 2022

Read More »

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

June 14, 2022

Read More »

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

June 9, 2022

Read More »

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 6, 2022

Read More »

InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 2, 2022

Read More »